Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Huntington disease
Biotech
JPM23: Annexon looks for '2 ways to win' in Huntington's trial
Annexon's CEO said at JPM that the company is giving itself "two ways to win" in the upcoming phase 2/3 trial for Huntington’s disease drug ANX005.
Annalee Armstrong
Jan 11, 2023 12:55pm
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Dec 14, 2022 7:15am
UniQure set to resume dosing in open-label Huntington's trial
Nov 2, 2022 10:18am
3 patients hospitalized in uniQure Huntington's disease trial
Aug 8, 2022 11:45am
Will Annexon's Huntington's data smooth over worried investors?
Jun 7, 2022 6:30am
Sage's Alzheimer's drug may improve cognitive performance
Apr 1, 2022 10:29am
